Try GOLD - Free

Why Singapore is Deep Tech Innovation Frontrunner

BioSpectrum Asia

|

March 2024

Move over Artificial Intelligence Al) and Machine Learning ML), there's a new technology on the block Deep Tech. This latest technology holds immense potential for the life sciences industry, and Singapore is leaving no stone unturned in becoming a deep tech hub. From strategic investments to collaborative initiatives and a supportive regulatory environment, read on to find out about the country's initiatives in becoming a deep tech superpower.

- Ayesha Siddiqui

Why Singapore is Deep Tech Innovation Frontrunner

Singapore has emerged as a significant player S in the global deep tech landscape. Over the past decade, the government has committed more than S$19 billion to advance research and development in deep tech, according to the Sparkmate report.

There are several initiatives aimed to strengthen the startup landscape in this sector. One key initiative driving Singapore's deep tech agenda is the Singapore Deep-Tech Alliance (SDTA), which facilitates partnerships and provides avenues for companies to create new startups, bring existing ones to market, find solutions to challenges, and access protected technologies. This initiative enhances collaboration and accelerates the growth of deep tech ventures within Singapore's ecosystem.

In addition, Singapore launched A*StartCentral (A*SC) in 2016, a first-of-its-kind open innovation platform by the Agency for Science Technology and Research (A*STAR). It aims to incubate and accelerate the growth of deep tech startups, and serves to bolster the startup ecosystem, including areas such as medtech and life sciences. Now it has over 150 deep tech startups.

"A*StartCentral (A*SC), a key player in Singapore's deep tech ecosystem, empowers earlystage startups in their entrepreneurial journey. By providing guidance and support, A*StartCentral enables startups to expand beyond Singapore and tap into global markets, fostering innovation and entrepreneurship on an international scale," said Emily Liew, Assistant Chief Executive Officer, Innovation & Enterprise Services, Enterprise Singapore.

A*SC builds upon the foundation of an open innovation community to foster crosspollination and interaction amongst researchers, corporates, startups, investors and entrepreneurs across diverse disciplines. A*SC will continue to inspire, innovate with, and empower researcherentrepreneurs in building successful, deep technology enabled ventures.

MORE STORIES FROM BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

Waters launches charge detection mass spectrometry technology

US-based Waters Corporation has unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS), delivering unmatched measurement and characterisation for the broadest range of mega-mass biomolecules central to next-generation therapeutics and structural biology.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Chulalongkorn University launches Thailand's first master's programme in Nurse Anesthesia

The Faculty of Nursing, Chulalongkorn University, has officially launched the \"Master of Nursing Science Programme in Nurse Anesthesia\" - the first of its kind in Thailand.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

WHO strengthens coordination for NTD programmes and supply chain delivery

The World Health Organization (WHO), together with health ministries, pharmaceutical donours, implementing partners and technical support platforms, is strengthening coordination for neglected tropical disease (NTD) programmes and supply chain delivery, through three major back-to-back meetings in Geneva.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

All-in-one coronavirus vaccines to save millions in future pandemics

A new study reveals that vaccines designed to protect against a wide range of coronaviruses could dramatically reduce deaths and economic disruption and limit the need for lockdowns in the event of another global coronavirus pandemic.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

NTU in Singapore introduces Master of Science course in Chinese Medicine

From 2026, Nanyang Technological University (NTU) in Singapore will start offering a Master of Science in Chinese Medicine to develop highly skilled postgraduates with advanced expertise in both the theoretical foundations and practical applications of Chinese medicine.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

ProSpecBio launches Activin-A recombinant protein for brain injury research

Israel-based ProSpecBio, an evolving biotech company dedicated to providing highly purified proteins to the global research community, has announced the launch of its latest product: CHO cell-derived recombinant Activin-A, now available for immediate delivery worldwide.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

PAHO publishes guide for designing AI instructions in public health

The Pan American Health Organization (PAHO) has launched a new guide providing practical advice on how to create Artificial Intelligence (AI) prompts that generate reliable, relevant, and culturally appropriate content across diverse contexts.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Prerna launches India's first MicroRNA based blood test for breast cancer screening

Precision RNA Biotech (Prerna), a healthcare startup from Hyderabad, India has announced the launch of Cantel, India's first microRNA-based blood test for breast cancer screening.

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Poly Medicure announces acquisition of Citieffe Group for Rs 324 Cr

India-based medtech firm Poly Medicure has announced signing of a definitive agreement to acquire 100 per cent stake in Medistream SA (Group) consisting of Citieffe SRL and its step-down subsidiaries in USA & Mexico, at an Enterprise Value of Rs 324 crore (EUR 31 million).

time to read

1 min

BioSpectrum Asia Nov 2025

BioSpectrum Asia

BioSpectrum Asia

Sumitomo, Novo Nordisk to co-promote obesity drug Wegovy in Japan

Sumitomo Pharma and Novo Nordisk Pharma have entered into a co-promotion agreement in Japan for Wegovy Subcutaneous Injection, a once-weekly subcutaneous injection formulation of GLP-1 receptor agonist indicated for the treatment of obesity disease.

time to read

1 min

BioSpectrum Asia Nov 2025

Listen

Translate

Share

-
+

Change font size